ES2157208T3 - Composicion y procedimiento para la reduccion del riesgo de hipotension. - Google Patents

Composicion y procedimiento para la reduccion del riesgo de hipotension.

Info

Publication number
ES2157208T3
ES2157208T3 ES93117796T ES93117796T ES2157208T3 ES 2157208 T3 ES2157208 T3 ES 2157208T3 ES 93117796 T ES93117796 T ES 93117796T ES 93117796 T ES93117796 T ES 93117796T ES 2157208 T3 ES2157208 T3 ES 2157208T3
Authority
ES
Spain
Prior art keywords
composition
risk
patient
hypotension
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93117796T
Other languages
English (en)
Inventor
David A Mark
Gary Pace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2157208T3 publication Critical patent/ES2157208T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

UNA TERAPIA PARA REDUCIR EL RIESGO A LA HIPOTENSION PARA UN PACIENTE CON RIESGO DE PADECERLA. SEGUN LA PRESENTE INVENCION, SE UTILIZA UNA COMPOSICION QUE CONTIENE UN CONTENIDO DE ARGININA LO SUFICIENTEMENTE REDUCIDO COMO PARA REDUCIR LA FORMACION DE OXIDO NITRICO EN EL PACIENTE Y PROPORCIONAR UNA COMPOSICION ENTERAL PARA UN PACIENTE CON RIESGO DE PADECER HIPOTENSION. EN UN ASPECTO DE LA INVENCION, LA COMPOSICION INCLUYE MENOS DE UN 0,2% APROXIMADAMENTE DEL TOTAL DE CALORIAS DE LA ARGININA. PREFERENTEMENTE, LA COMPOSICION PROPORCIONA LOS REQUISITOS NUTRITIVOS NECESARIOS AL PACIENTE.
ES93117796T 1992-11-05 1993-11-03 Composicion y procedimiento para la reduccion del riesgo de hipotension. Expired - Lifetime ES2157208T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/971,949 US5356873A (en) 1992-11-05 1992-11-05 Method for providing nutritional requirements to patients having a chronic inflammation reaction

Publications (1)

Publication Number Publication Date
ES2157208T3 true ES2157208T3 (es) 2001-08-16

Family

ID=25518983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93117796T Expired - Lifetime ES2157208T3 (es) 1992-11-05 1993-11-03 Composicion y procedimiento para la reduccion del riesgo de hipotension.

Country Status (11)

Country Link
US (1) US5356873A (es)
EP (1) EP0612522B1 (es)
JP (1) JPH0797332A (es)
AT (1) ATE200734T1 (es)
AU (1) AU5040593A (es)
CA (1) CA2109392A1 (es)
DE (1) DE69330177T2 (es)
DK (1) DK0612522T3 (es)
ES (1) ES2157208T3 (es)
GR (1) GR3036272T3 (es)
PT (1) PT612522E (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585402A (en) * 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5378722A (en) * 1993-12-03 1995-01-03 Clintec Nutrition Co. Nutritional compositions for management of nitrogen metabolism
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
JP2002543147A (ja) * 1999-04-29 2002-12-17 ノボ ノルディスク アクティーゼルスカブ ブラジキニン放出の阻害におけるヘパリン結合アンタゴニストの使用
US6833350B2 (en) 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
US8501676B2 (en) * 2004-07-19 2013-08-06 N.V. Nutricia Preparation for use of aspartate for regulating glucose levels in blood
CA2778823A1 (en) * 2006-04-04 2007-10-11 Nestec S.A. Treatments using citrulline
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
CA2116684A1 (en) * 1991-09-27 1993-04-01 Robert G. Kilbourn Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies

Also Published As

Publication number Publication date
ATE200734T1 (de) 2001-05-15
EP0612522A1 (en) 1994-08-31
PT612522E (pt) 2001-08-30
GR3036272T3 (en) 2001-10-31
DE69330177T2 (de) 2001-09-06
DE69330177D1 (de) 2001-05-31
JPH0797332A (ja) 1995-04-11
EP0612522B1 (en) 2001-04-25
AU5040593A (en) 1994-05-19
US5356873A (en) 1994-10-18
DK0612522T3 (da) 2001-08-13
CA2109392A1 (en) 1994-05-06

Similar Documents

Publication Publication Date Title
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
EP0303915A3 (en) Retinoids for the treatment of skin damaged by light
EP0590076A4 (en) Production of human hemoglobin in transgenic pigs
EP0614616A3 (en) Composition for the treatment of patients with liver diseases.
EP0690722A4 (en) COMPOSITION AND METHOD FOR REDUCING THE TOXICITY OF BIOLOGICALLY ACTIVE FACTORS
EP0222483A3 (en) Use of gamma-linolenic acid and related compounds in the treatment of endometriosis
ES2157208T3 (es) Composicion y procedimiento para la reduccion del riesgo de hipotension.
GR3025178T3 (en) Medicament for the treatment of vulvar dystrophy or vaginal dryness
KR910005858A (ko) 지방산 요법
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE160502T1 (de) Kosmetische und dermatologische formulierungen mit einem wirksamen gehalt an cis-urocaninsäure
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
IL85346A (en) Pharmaceutical compositions containing blood coagulation factor xiii
AU3423493A (en) Methods and compositions for reducing blood loss
EP0158880A3 (en) Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
DK0434989T3 (da) Fremgangsmåde til forbedring af ventilationen under søvn og til behandling af søvnrelaterede ventilationsabnormaliteter
KR900017599A (ko) 종양 치료용 약학 조성물
ZA978879B (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders.
ATE302611T1 (de) Humanes wachstumshormon als hilfe gegen unterkühlung
TW217382B (es)
Francois et al. Role of iron overload and chelating agents in Yersinia infections on thalassaemia major.
UA8273A (uk) Спосіб лікування опіків при багатофакторному пошкодженні

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612522

Country of ref document: ES